The impact of GLP-1 RAs on mortality, MACEs, and MAKEs The crude incidence of mortality rate was 22.91 per 1000 person-years, which was significantly lower in the GLP-1 RAs users group than in the non-users group (6.8% vs. 12.9%; aHR: 0.57, 95% CI: 0.51–0.64) (Table 2, Table...
This chapter aims to review: (i) T2DM and obesity as CVD risk factors; (ii) previous clinical trials with neutral, deleterious, or beneficial results; (iii) why GLP-1RAs are an interesting class of drugs in the context of the metabolic syndrome; (iv) up-to-date information about GLP-1...
Other industries have already jumped at the opportunity to appeal to the growing consumer base of Ozempic users.Nestlérolled out a line ofsmaller-portioned frozen mealsspecifically for users of GLP-1 meds. WeightWatcherslaunched a planoffering weight-loss drugs like Wegovy. ...
Slow food: Sustained impact of harder foods on the reduction in energy intake over the course of the day. PLoS ONE. 2014;9:1–7. Article CAS Google Scholar Zhu Y, Hsu WH, Hollis JH. The effect of food form on satiety. Int J Food Sci Nutr. 2013;64:385–91. Article CAS PubMed...
After gastric bypass surgery, postprandial plasma GLP-1 can increase substantially [37], and the effects of GLP-1 on intestinal motility in human are weaker [38]. In our trial, patients received Roux-en-Y gastrojejunostomy, and the GT group had a short time to tolerance of solid food. ...
(iGlarLixi) investigated the safety and efficacy of iGlarLixi versus iGlar: LixiLan-O (NCT02058147) in patients with type 2 diabetes (T2D) inadequately controlled on oral antidiabetes drugs (OADs) and LixiLan-L (NCT02058160) in patients with T2D inadequately controlled on basal insulin卤OAD...
and guidelines support the use of GLP-1 RAs as a second-line option, in combi- nation with metformin, sulfonylureas, thiazolidinediones, and/or in combination with basal insulin as an alternative to prandial insulin.6,7 There are, however, important within-class differences between the drugs. ...
Given that GLP-1 is released in response to intestinal glucose, manipulation of the gut microbiota could improve whole-body glucose homeostasis via changes in intestinal glucose-sensing pathways. Here, using in vivo upper small intestinal-targeted molecular and chemical approaches, we evaluate whether ...
Roux-en-Y gastric bypass (RYGB) is a gold-standard procedure for treatment of obesity and associated comorbidities. No consensus on the optimal design of this operation has been achieved, with various lengths of bypassed small bowel limb lengths being used by bariatric surgeons. This aim of this...
By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection. See our privacy policy for more information on the use of your perso...